73 related articles for article (PubMed ID: 8235691)
1. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract][Full Text] [Related]
2. Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.
Klintman J; Appleby N; Stamatopoulos B; Ridout K; Eyre TA; Robbe P; Pascua LL; Knight SJL; Dreau H; Cabes M; Popitsch N; Ehinger M; Martín-Subero JI; Campo E; Månsson R; Rossi D; Taylor JC; Vavoulis DV; Schuh A
Blood; 2021 May; 137(20):2800-2816. PubMed ID: 33206936
[TBL] [Abstract][Full Text] [Related]
3. Th17/IL-17A might play a protective role in chronic lymphocytic leukemia immunity.
Hus I; Bojarska-Junak A; Chocholska S; Tomczak W; Woś J; Dmoszyńska A; Roliński J
PLoS One; 2013; 8(11):e78091. PubMed ID: 24223764
[TBL] [Abstract][Full Text] [Related]
4. The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.
Matutes E; Bosanquet AG; Wade R; Richards SM; Else M; Catovsky D
Leukemia; 2013 Feb; 27(2):507-10. PubMed ID: 22810506
[No Abstract] [Full Text] [Related]
5. Functional cure reported in CLL.
Davids MS
Blood; 2023 Nov; 142(21):1761-1763. PubMed ID: 37995104
[No Abstract] [Full Text] [Related]
6. Current and developing chemotherapy for CLL.
Montserrat E
Med Oncol; 2002; 19 Suppl():S11-9. PubMed ID: 12180487
[TBL] [Abstract][Full Text] [Related]
7. Therapy of chronic lymphocytic leukemia patients. Results from the French cooperative trials. French Cooperative Group on Chronic Lymphocytic Leukemia.
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):443-8. PubMed ID: 3065741
[TBL] [Abstract][Full Text] [Related]
8. Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
Adiga GU; Abebe L; Wiernik PH
Am J Hematol; 2003 Apr; 72(4):267-73. PubMed ID: 12666139
[TBL] [Abstract][Full Text] [Related]
9. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
[TBL] [Abstract][Full Text] [Related]
10. CHOP regimen versus intermittent chlorambucil-prednisone in stage B chronic lymphocytic leukemia. Short term results from a randomized clinical trial. French Cooperative Group on Chronic Lymphocytic Leukemia.
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):449-52. PubMed ID: 2906118
[TBL] [Abstract][Full Text] [Related]
11. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
[TBL] [Abstract][Full Text] [Related]
12. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
13. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
[TBL] [Abstract][Full Text] [Related]
14. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
